Close

Anti-Peptide FEA T cell receptor ((B3K506)-3), pCDTCR1 (TCR-YC0901)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The tight threshold that regulates whether B3K508 or B3K506 CD4 T cells undergo robust expansion is set by the potency of virally expressed peptide ligand and by the density in which it is presented. The B3K508 and B3K506 TCRs engage the series of virally expressed pMHC ligands with different binding kinetics.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • Peptide FEA
  • Epitope
  • FEAQKARANKAVD
  • Format
  • Non-Modified TCR
  • Allele
  • H2-IAb
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • B3K506
  • Host Species
  • Mouse

Target

  • Introduction
  • Upon infection, CD4 T cells scan antigen-presenting cells (APCs) for pathogen-derived peptides displayed on host MHC class II proteins (pMHCII). If a T-cell–APC encounter results in intracellular signals that exceed a threshold, naïve CD4 T cells are triggered to undergo clonal expansion and acquire effector cell functions that help eliminate pathogens.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Mouse anti-Peptide FEA T cell receptor ((B3K506)-3), pCDTCR1 (TCR-YC0901). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.